Phase 1/2 study of triple combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for chemotherapy-naïve stageIIIB/IV non- squamous non-small-cell lung cancer (TORG1424/OLCSG1402)
Phase of Trial: Phase I/II
Latest Information Update: 26 Apr 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Apr 2019 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.